Key result
Case report details treatment for primary pulmonary malignant fibrous histiocytoma, comprising ~0.2% of pulmonary neoplasms.
Case Report (n=1)
This case report adds to the limited literature on primary pulmonary malignant fibrous histiocytoma, a rare neoplasm constituting less than 0.2% of all pulmonary neoplasms.
May raise suspicion for rare pulmonary sarcomas; extends sparse literature but leaves management questions open.
Malignant fibrous histiocytoma (MFH) cases are classified within the group of nonclassified sarcomas. The etiopathogenesis is unclear; however, MFH commonly develops in scar tissue and in areas exposed to radiation. MFH is the most common soft tissue sarcoma in adults and may be borne in the lungs, chest wall, mediastinum, or other tissues. Primary MFH of the lung constitutes less than 0.2% of all pulmonary neoplasms; thus, an optimal treatment strategy has not yet been elucidated. We aimed to report a case of MFH of the lung with subsequent treatment administration.
No takes yet. Share an insight, caveat, or question.
Coşgun et al. (2017) conducted a case report in Primary Pulmonary Malignant Fibrous Histiocytoma (n=1). A case of primary pulmonary malignant fibrous histiocytoma, a rare soft tissue sarcoma constituting less than 0.2% of all pulmonary neoplasms, is reported along with its subsequent treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: